1-4 of 4
Mohamad Sobh, Pharm., M.
Close
Sort by
Journal Articles

Azacitidine Use in MDS and AML Patients: Best Selection for Better Results

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm. M., Stéphane Morisset, Stat., Carine Champigneulle, CRA, Florence Ranchon, Marie Y. Detrait, MD, Hélène Labussière-Wallet, MD, Sophie Ducastelle, MD, Franck E. Nicolini, MD, PhD, Youcef Chelghoum, MD, Xavier Thomas, MD, Caroline Le jeune, MD, Eric Wattel, MD, PhD, Catherine Rioufol, PharmD, Fiorenza Barraco, MD
Journal: Blood
Blood (2012) 120 (21): 5070.
https://doi.org/10.1182/blood.V120.21.5070.5070
Published: 2012
Journal Articles

The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Lila Gilis, MD, Madeleine Etienne, CRA, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Helene Labussiere, MD, Luc Gerland, MD, Damien Waz, MStud, Mohamad Sobh, Pharm., M, Stephane Morisset, Stat., Mauricette Michallet
Journal: Blood
Blood (2010) 116 (21): 3407.
https://doi.org/10.1182/blood.V116.21.3407.3407
Published: 2010
Journal Articles

Clinical Phenotype and Response to Imatinib of Chronic Myelogenous Leukemia Patients Harbouring Atypical BCR-ABL Transcripts. A Retrospective Analysis From the French Group of CML (Fi-LMC) and the French Group of Molecular Biologists for Hematological Malignancies (GBMHM).

Benedicte Deau, MD, Mathias Montveneur, MStud, Valérie Coiteux, MD, Aline Renneville, MD, Francoise Rigal-Huguet, MD, Eric Delabesse, MD, PhD, Michel Tulliez, MD, Dominique Bories, MD, PhD, Aude Charbonnier, MD, PhD, Marie-Joelle Mozziconacci, MD, PhD, Thibault Legay, MD, Eric Lippert, PhD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Jean-Michel Cayuela, PhD, Shanti Amé, MD, Marie-Pierre Gaub, MD, Martine Gardembas, MD, Odile Blanchet, MD, Bruno Audhuy, MD, Agnès Buzyn, MD, PhD, Elisabeth Mac Intyre, MD, PhD, Anna-Lisa Andreoli, MD, Oumedaly Reman, Nathalie Contentin, MD, Christian Bastard, MD, Jean-Christophe Ianotto, MD, Valérie Ugo, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Said Brahimi, MD, Viviane Dubruille, Jean-Francois Brantus, MD, Mohamad Sobh, Pharm., M., Stephane Morisset, Stat., Claude Preudhomme, MD, PhD, Sandrine Hayette, PhD, Franck E Nicolini, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3378.
https://doi.org/10.1182/blood.V116.21.3378.3378
Published: 2010
Journal Articles

Erythropoietin Use In Patients with AML or Undergoing Allogeneic HSCT Significantly Improves Quality of Life and Reduces Red Blood Cells and Platelets Transfusions without Any Survival Effect.

Mauricette Michallet, Karine Goldet, CRA, Stephane Morisset, Stat., Mohamad Sobh, Pharm., M., Youcef Chelghoum, MD, Xavier Thomas, MD, PhD, Helene Labussiere, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Jean Vial, Catherine Renzullo, Pharm., Carole Paillet, Pharm., Christine Pivot, Pharm., Perrine Badol-Van Straaten, Angelique Denis, Anne Termoz, Franck E Nicolini, MD, PhD, Isabelle Jaisson-Hot
Journal: Blood
Blood (2010) 116 (21): 3810.
https://doi.org/10.1182/blood.V116.21.3810.3810
Published: 2010